nach oben

Erschienen in:

10.03.2020 | Review Article

Biomarkers in traumatic brain injury: new concepts

verfasst von: Dana Slavoaca, Dafin Muresanu, Codruta Birle, Olivia Verisezan Rosu, Ioana Chirila, Iulia Dobra, Nicoleta Jemna, Stefan Strilciuc, Pieter Vos

Erschienen in: Neurological Sciences | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Traumatic brain injury is a multifaceted condition that encompasses a spectrum of injuries: contusions, axonal injuries in specific brain regions, edema, and hemorrhage. Brain injury determines a broad clinical and disability spectrum due to the implication of various cellular pathways, genetic phenotypes, and environmental factors. It is challenging to predict patient outcomes, to appropriately evaluate the patients, to determine a suitable treatment strategy and rehabilitation program, and to communicate with patient relatives. Biomarkers detected from body fluids are potential evaluation tools for traumatic brain injury patients. These may serve as internal indicators of cerebral damage, delivering valuable information about the dynamic cellular, biochemical, and molecular environments. The diagnostic and prognostic value of biomarkers tested both in animal models of traumatic brain injury is still under question, despite a considerable scientific literature. Recent publications emphasize that a more realistic approach involves combining multiple types of biomarkers with other investigative tools (imaging, outcome scales, and genetic polymorphisms). Additionally, there is increasing interest in the use of biomarkers as tools for treatment monitoring and as surrogate outcome variables to facilitate the design of distinct randomized controlled trials. This review highlights the latest available evidence regarding biomarkers in adults after traumatic brain injury and discusses new approaches in the evaluation of this patient group.

Povlishock JT, Katz DI (2005) Update of neuropathology and neurological recovery after traumatic brain injury. J Head Trauma Rehabil 20(1):76–94PubMed

Dixon KJ (2017) Pathophysiology of traumatic brain injury. Phys Med Rehabil Clin N Am 28(2):215–225PubMed

Xiong Y, Mahmood A, Chopp M (2018) Current understanding of neuroinflammation after traumatic brain injury and cell-based therapeutic opportunities. Chin J Traumatol 21(3):137–151PubMedPubMedCentral

Johnson VE, Stewart W, Smith DH (2013) Axonal pathology in traumatic brain injury. Exp Neurol 246:35–43PubMed

Bigler ED (2001) Distinguished Neuropsychologist Award Lecture 1999. The lesion(s) in traumatic brain injury: implications for clinical neuropsychology. Arch Clin Neuropsychol 16(2):95–131PubMed

LoBue C, Woon FL, Rossetti HC, Hynan LS, Hart J, Cullum CM (2018) Traumatic brain injury history and progression from mild cognitive impairment to Alzheimer disease. Neuropsychology 32(4):401–409PubMedPubMedCentral

Undén J, Ingebrigtsen T, Romner B (2013) Scandinavian Neurotrauma Committee (SNC). Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults: an evidence and consensus-based update. BMC Med 11:50PubMedPubMedCentral

Mondello S, Sorinola A, Czeiter E, Vámos Z, Amrein K, Synnot A et al (2017) Blood-based protein biomarkers for the management of traumatic brain injuries in adults presenting with mild head injury to emergency departments: a living systematic review and meta-analysis. J Neurotrauma 12

FDA approves Banyan Biomarkers’ traumatic brain injury blood test – Office of Research [Internet]. [cited 2018]. Available from: https://research.ufl.edu/banyanbiomarkers.html

10.

Shahjouei S, Sadeghi-Naini M, Yang Z, Kobeissy F, Rathore D, Shokraneh F, Blackburn S, Manley GT, Wang KKW (2018) The diagnostic values of UCH-L1 in traumatic brain injury: a meta-analysis. Brain Inj 32(1):1–17PubMed

11.

Luoto TM, Raj R, Posti JP, Gardner AJ, Panenka WJ, Iverson GL (2017) A systematic review of the usefulness of glial fibrillary acidic protein for predicting acute intracranial lesions following head trauma. Front Neurol 8:652PubMedPubMedCentral

12.

Gan ZS, Stein SC, Swanson R, Guan S, Garcia L, Mehta D, Smith DH (2019) Blood biomarkers for traumatic brain injury: a quantitative assessment of diagnostic and prognostic accuracy. Front Neurol 10:446PubMedPubMedCentral

13.

Mahan MY, Thorpe M, Ahmadi A, Abdallah T, Casey H, Sturtevant D et al (2019) Glial fibrillary acidic protein (GFAP) outperforms S100 calcium-binding protein B (S100B) and ubiquitin C-terminal hydrolase L1 (UCH-L1) as predictor for positive computed tomography of the head in trauma subjects. World Neurosurg 128:e434–e444PubMed

14.

Lagerstedt L, Egea-Guerrero JJ, Rodríguez-Rodríguez A, Bustamante A, Montaner J, El Rahal A et al (2018) Early measurement of interleukin-10 predicts the absence of CT scan lesions in mild traumatic brain injury. PLoS One 13(2):e0193278PubMedPubMedCentral

15.

Lagerstedt L, Egea-Guerrero JJ, Bustamante A, Montaner J, Rodríguez-Rodríguez A, El Rahal A et al (2017) H-FABP: a new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury. PLoS One 12(4):e0175572PubMedPubMedCentral

16.

Sharma R, Rosenberg A, Bennett ER, Laskowitz DT, Acheson SK (2017) A blood-based biomarker panel to risk-stratify mild traumatic brain injury. PLoS One 12(3):e0173798PubMedPubMedCentral

17.

Korley FK, Yue JK, Wilson D, Hrusovsky K, Diaz-Arrasta R, Ferguson AR et al (2018) Performance evaluation of a multiplex assay for simultaneous detection of four clinically relevant TBI biomarkers. J Neurotrauma 25

18.

Rubenstein R, Chang B, Yue JK, Chiu A, Winkler EA, Puccio AM, Diaz-Arrastia R, Yuh EL, Mukherjee P, Valadka AB, Gordon WA, Okonkwo DO, Davies P, Agarwal S, Lin F, Sarkis G, Yadikar H, Yang Z, Manley GT, Wang KKW, the TRACK-TBI Investigators ,Cooper SR, Dams-O'Connor K, Borrasso AJ, Inoue T, Maas AIR, Menon DK, Schnyer DM, Vassar MJ Comparing plasma phospho tau, total tau, and phospho tau-total tau ratio as acute and chronic traumatic brain injury biomarkers. JAMA Neurol. 2017;74(9):1063–1072

19.

Dickens AM, Posti JP, Takala RS, Ala-Seppälä HM, Mattila I, Coles JC et al (2018) Serum metabolites associate with CT findings following TBI. J Neurotrauma 35(22):2673–2683PubMed

20.

Tsitsopoulos PP, Abu Hamdeh S, Marklund N (2017) Current opportunities for clinical monitoring of axonal pathology in traumatic brain injury. Front Neurol 8:599PubMedPubMedCentral

21.

Zemlan FP, Rosenberg WS, Luebbe PA, Campbell TA, Dean GE, Weiner NE, Cohen JA, Rudick RA, Woo D (1999 Feb) Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem 72(2):741–750PubMed

22.

Marklund N, Farrokhnia N, Hånell A, Vanmechelen E, Enblad P, Zetterberg H, Blennow K, Hillered L (2014) Monitoring of β-amyloid dynamics after human traumatic brain injury. J Neurotrauma 31(1):42–55PubMed

23.

Tomita K, Nakada TA, Oshima T, Motoshima T, Kawaguchi R, Oda S (2019) Tau protein as a diagnostic marker for diffuse axonal injury. PLoS One 14(3):e0214381PubMedPubMedCentral

24.

Mondello S, Jeromin A, Buki A, Bullock R, Czeiter E, Kovacs N, Barzo P, Schmid K, Tortella F, Wang KK, Hayes RL (2012) Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma 29(6):1096–1104PubMedPubMedCentral

25.

Kukacka J, Vajtr D, Huska D, Průsa R, Houstava L, Samal F et al (2006) Blood metallothionein, neuron specific enolase, and protein S100B in patients with traumatic brain injury. Neuro Endocrinol Lett 27(Suppl 2):116–120PubMed

26.

Papa L, Robicsek SA, Brophy GM, Wang KKW, Hannay HJ, Heaton S, Schmalfuss I, Gabrielli A, Hayes RL, Robertson CS (2018) Temporal profile of microtubule-associated protein 2: a novel indicator of diffuse brain injury severity and early mortality after brain trauma. J Neurotrauma 35(1):32–40PubMedPubMedCentral

27.

Abu Hamdeh S, Shevchenko G, Mi J, Musunuri S, Bergquist J, Marklund N. Proteomic differences between focal and diffuse traumatic brain injury in human brain tissue. Sci Rep [Internet]. 2018 Dec [cited 2018 Jul 6];8(1). Available from: http://www.nature.com/articles/s41598-018-25060-0

28.

Wood H. Traumatic brain injury: Evidence of blood–brain barrier disruption after concussion [Internet]. Nature Reviews Neurology. 2018 [cited 2018 Jun 6]. Available from: https://www.nature.com/articles/nrneurol.2018.29

29.

Blyth BJ, Farhavar A, Gee C, Hawthorn B, He H, Nayak A, Stöcklein V, Bazarian JJ (2009) Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. J Neurotrauma 26(9):1497–1507PubMedPubMedCentral

30.

Blyth BJ, Farahvar A, He H, Nayak A, Yang C, Shaw G, Bazarian JJ (2011 Dec) Elevated serum ubiquitin carboxy-terminal hydrolase L1 is associated with abnormal blood-brain barrier function after traumatic brain injury. J Neurotrauma 28(12):2453–2462PubMed

31.

Vajtr D, Benada O, Kukacka J, Průsa R, Houstava L, Toupalík P, Kizek R (2009) Correlation of ultrastructural changes of endothelial cells and astrocytes occurring during blood brain barrier damage after traumatic brain injury with biochemical markers of BBB leakage and inflammatory response. Physiol Res 58(2):263–268PubMed

32.

Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA (2009) Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery 65(4):702–708PubMedPubMedCentral

33.

Jha RM, Puccio AM, Chou SH-Y, Chang C-CH, Wallisch JS, Molyneaux BJ et al (2017) Sulfonylurea receptor-1: a novel biomarker for cerebral edema in severe traumatic brain injury. Crit Care Med 45(3):e255–e264PubMedPubMedCentral

34.

Mellergård P, Åneman O, Sjögren F, Säberg C, Hillman J (2011) Differences in cerebral extracellular response of interleukin-1β, interleukin-6, and interleukin-10 after subarachnoid hemorrhage or severe head trauma in humans. Neurosurgery. 68(1):12–19 discussion 19PubMed

35.

Mellergård P, Sjögren F, Hillman J (2010) Release of VEGF and FGF in the extracellular space following severe subarachnoidal haemorrhage or traumatic head injury in humans. Br J Neurosurg 24(3):261–267PubMed

36.

Kirchhoff C, Buhmann S, Braunstein V, Leidel BA, Vogel T, Kreimeier U et al (2008) Cerebrospinal s100-B: a potential marker for progressive intracranial hemorrhage in patients with severe traumatic brain injury. Eur J Med Res 13(11):511–516PubMed

37.

Vedin T, Karlsson M, Edelhamre M, Bergenheim M, Larsson PA (2019) Features of urine S100B and its ability to rule out intracranial hemorrhage in patients with head trauma: a prospective trial. Eur J Trauma Emerg Surg 6

38.

Tian H-L, Chen H, Wu B-S, Cao H-L, Xu T, Hu J et al (2010) D-Dimer as a predictor of progressive hemorrhagic injury in patients with traumatic brain injury: analysis of 194 cases. Neurosurg Rev 33(3):359–365 discussion 365-366PubMed

39.

Fair K, Farrell D, McCully B, Rick E, Dewey EN, Hilliard C et al (2019) Fibrinolytic activation in patients with progressive intracranial hemorrhage after traumatic brain injury. Neurotrauma

40.

Adrian H, Mårten K, Salla N, Lasse V (2016) Biomarkers of traumatic brain injury: temporal changes in body fluids. eNeuro 3(6)

41.

Thelin EP, Zeiler FA, Ercole A, Mondello S, Büki A, Bellander B-M et al (2017) Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: a systematic review. Front Neurol 8:300PubMedPubMedCentral

42.

Wang KK, Yang Z, Zhu T, Shi Y, Rubenstein R, Tyndall JA, Manley GT (2018) An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn 18(2):165–180PubMedPubMedCentral

43.

Mercier E, Tardif P-A, Cameron PA, Batomen Kuimi BL, Émond M, Moore L, Mitra B, Frenette J, de Guise E, Ouellet MC, Bordeleau M, le Sage N (2018) Prognostic value of S-100β protein for prediction of post-concussion symptoms after a mild traumatic brain injury: systematic review and meta-analysis. J Neurotrauma 35(4):609–622PubMed

44.

Mercier E, Boutin A, Lauzier F, Fergusson DA, Simard J-F, Zarychanski R et al (2013) Predictive value of S-100β protein for prognosis in patients with moderate and severe traumatic brain injury: systematic review and meta-analysis. BMJ 346:f1757PubMed

45.

Papa L, Brophy GM, Welch RD, Lewis LM, Braga CF, Tan CN, Ameli NJ, Lopez MA, Haeussler CA, Mendez Giordano DI, Silvestri S, Giordano P, Weber KD, Hill-Pryor C, Hack DC (2016) Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol 73(5):551–560PubMed

46.

Lei J, Gao G, Feng J, Jin Y, Wang C, Mao Q et al (2015) Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study. Crit Care Lond Engl 19:362

47.

Mercier E, Tardif P-A, Cameron PA, Émond M, Moore L, Mitra B, Ouellet MC, Frenette J, de Guise E, le Sage N (2018) Prognostic value of neuron-specific enolase (NSE) for prediction of post-concussion symptoms following a mild traumatic brain injury: a systematic review. Brain Inj 32(1):29–40PubMed

48.

Mondello S, Linnet A, Buki A, Robicsek S, Gabrielli A, Tepas J, Papa L, Brophy GM, Tortella F, Hayes RL, Wang KK (2012) Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery. 70(3):666–675PubMedPubMedCentral

49.

Lorente L (2017) Biomarkers associated with the outcome of traumatic brain injury patients. Brain Sci 27:7(11)

50.

Bogoslovky T, Wilson D, Chen Y, Hanlon D, Gill J, Jeromin A, Song L, Moore C, Gong Y, Kenney K, Diaz-Arrastia R (2017) Increases of plasma levels of glial fibrillary acidic protein, tau, and amyloid β up to 90 days after traumatic brain injury. J Neurotrauma 34(1):66–73

51.

Magnoni S, Esparza TJ, Conte V, Carbonara M, Carrabba G, Holtzman DM, Zipfel GJ, Stocchetti N, Brody DL (2012) Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain J Neurol 135(Pt 4):1268–1280

52.

Liliang P-C, Liang C-L, Weng H-C, Lu K, Wang K-W, Chen H-J, Chuang JH (2010) Tau proteins in serum predict outcome after severe traumatic brain injury. J Surg Res 160(2):302–307PubMed

53.

Mondello S, Gabrielli A, Catani S, D’Ippolito M, Jeromin A, Ciaramella A et al (2012) Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury. Brain Inj 26(13–14):1629–1635PubMed

54.

Darwish RS, Amiridze NS (2010) Detectable levels of cytochrome C and activated caspase-9 in cerebrospinal fluid after human traumatic brain injury. Neurocrit Care 12(3):337–341PubMed

55.

Uzan M, Erman H, Tanriverdi T, Sanus GZ, Kafadar A, Uzun H (2006) Evaluation of apoptosis in cerebrospinal fluid of patients with severe head injury. Acta Neurochir 148(11):1157–1164 discussionPubMed

56.

Lorente L, Martín MM, Argueso M, Ramos L, Solé-Violán J, Riaño-Ruiz M et al (2015) Serum caspase-3 levels and mortality are associated in patients with severe traumatic brain injury. BMC Neurol 15:228PubMedPubMedCentral

57.

Lenzlinger PM, Marx A, Trentz O, Kossmann T, Morganti-Kossmann MC (2002) Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans. J Neuroimmunol 122(1–2):167–174PubMed

58.

Pineda JA, Lewis SB, Valadka AB, Papa L, Hannay HJ, Heaton SC, Demery JA, Liu MC, Aikman JM, Akle V, Brophy GM, Tepas JJ, Wang KK, Robertson CS, Hayes RL (2007) Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma 24(2):354–366PubMed

59.

Cardali S, Maugeri R (2006) Detection of alphaII-spectrin and breakdown products in humans after severe traumatic brain injury. J Neurosurg Sci 50(2):25–31PubMed

60.

Farkas O, Polgár B, Szekeres-Barthó J, Dóczi T, Povlishock JT, Büki A (2005) Spectrin breakdown products in the cerebrospinal fluid in severe head injury--preliminary observations. Acta Neurochir 147(8):855–861PubMed

61.

Brophy GM, Pineda JA, Papa L, Lewis SB, Valadka AB, Hannay HJ, Heaton SC, Demery JA, Liu MC, Tepas JJ 3rd, Gabrielli A, Robicsek S, Wang KK, Robertson CS, Hayes RL (2009) alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma 26(4):471–479

62.

Chen S, Shi Q, Zheng S, Luo L, Yuan S, Wang X, Cheng Z, Zhang W (2016) Role of α-II-spectrin breakdown products in the prediction of the severity and clinical outcome of acute traumatic brain injury. Exp Ther Med 11(5):2049–2053PubMedPubMedCentral

63.

Bayir A, Kalkan E, Koçak S, Ak A, Cander B, Bodur S (2006) Fibrinolytic markers and neurologic outcome in traumatic brain injury. Neurol India 54(4):363–365PubMed

64.

Morel N, Morel O, Petit L, Hugel B, Cochard J-F, Freyssinet J-M, Sztark F, Dabadie P (2008) Generation of procoagulant microparticles in cerebrospinal fluid and peripheral blood after traumatic brain injury. J Trauma 64(3):698–704PubMed

65.

Yokota H (2007) Cerebral endothelial damage after severe head injury. J Nippon Med Sch 74(5):332–337PubMed

66.

Yokota H, Naoe Y, Nakabayashi M, Unemoto K, Kushimoto S, Kurokawa A, Node Y, Yamamoto Y (2002) Cerebral endothelial injury in severe head injury: the significance of measurements of serum thrombomodulin and the von Willebrand factor. J Neurotrauma 19(9):1007–1015PubMed

67.

Hergenroeder GW, Moore AN, McCoy JP, Samsel L, Ward NH, Clifton GL et al (2010) Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury. J Neuroinflammation 7:19PubMedPubMedCentral

68.

Stein DM, Lindel AL, Murdock KR, Kufera JA, Menaker J, Scalea TM (2012) Use of serum biomarkers to predict secondary insults following severe traumatic brain injury. Shock Augusta Ga 37(6):563–568

69.

Dash PK, Redell JB, Hergenroeder G, Zhao J, Clifton GL, Moore A (2010) Serum ceruloplasmin and copper are early biomarkers for traumatic brain injury-associated elevated intracranial pressure. J Neurosci Res 88(8):1719–1726PubMed

70.

Perez-Barcena J, Ibáñez J, Brell M, Crespí C, Frontera G, Llompart-Pou JA, Homar J, Abadal JM (2011) Lack of correlation among intracerebral cytokines, intracranial pressure, and brain tissue oxygenation in patients with traumatic brain injury and diffuse lesions. Crit Care Med 39(3):533–540PubMed

71.

Jeter CB, Hergenroeder GW, Ward NH, Moore AN, Dash PK (2012) Human traumatic brain injury alters circulating L-arginine and its metabolite levels: possible link to cerebral blood flow, extracellular matrix remodeling, and energy status. J Neurotrauma 29(1):119–127PubMed

72.

Kunz M, Nussberger J, Holtmannspötter M, Bitterling H, Plesnila N, Zausinger S (2013) Bradykinin in blood and cerebrospinal fluid after acute cerebral lesions: correlations with cerebral edema and intracranial pressure. J Neurotrauma 30(19):1638–1644PubMed

73.

Moritz S, Warnat J, Bele S, Graf BM, Woertgen C (2010) The prognostic value of NSE and S100B from serum and cerebrospinal fluid in patients with spontaneous subarachnoid hemorrhage. J Neurosurg Anesthesiol 22(1):21–31PubMed

74.

Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, Zuccarello M (2002) C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res 947(1):131–139PubMed

75.

Stamataki E, Stathopoulos A, Garini E, Kokkoris S, Glynos C, Psachoulia C et al (2013) Serum S100B protein is increased and correlates with interleukin 6, hypoperfusion indices, and outcome in patients admitted for surgical control of hemorrhage. Shock 40(4):274–280PubMed

76.

Belli A, Sen J, Petzold A, Russo S, Kitchen N, Smith M (2008) Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study. Acta Neurochir 150(5):461–469 discussion 470PubMed

77.

Ali A, Konakondla S, Zwagerman NT, Peng C, Schafer S, Ding JY, Dornbos D 3rd, Sikharam C, Geng X, Guthikonda M, Kreipke CW, Rafols JA, Ding Y (2012) Glycerol accumulation in edema formation following diffuse traumatic brain injury. Neurol Res 34(5):462–468

78.

Ciaramella A, Della Vedova C, Salani F, Viganotti M, D’Ippolito M, Caltagirone C et al (2014) Increased levels of serum IL-18 are associated with the long-term outcome of severe traumatic brain injury. Neuroimmunomodulation. 21(1):8–12PubMed

79.

Zeiler FA, Thelin EP, Czosnyka M, Hutchinson PJ, Menon DK, Helmy A (2017) Cerebrospinal fluid and microdialysis cytokines in severe traumatic brain injury: a scoping systematic review. Front Neurol 8:331PubMedPubMedCentral

80.

Casault C, Al Sultan AS, Banoei M, Couillard P, Kramer A, Winston BW (2018) Cytokine responses in severe traumatic brain injury: where there is smoke, is there fire? Neurocrit Care 30(1):22–32

81.

Zhang ZY, Li J, Ye Q, Dong Y, Bao GM, Shen YK et al (2019) Usefulness of serum interleukin-33 as a prognostic marker of severe traumatic brain injury. Clin Chim Acta 497:6–12PubMed

82.

Roberts DJ, Jenne CN, Léger C, Kramer AH, Gallagher CN, Todd S, Parney IF, Doig CJ, Yong VW, Kubes P, Zygun DA (2013) Association between the cerebral inflammatory and matrix metalloproteinase responses after severe traumatic brain injury in humans. J Neurotrauma 30(20):1727–1736PubMed

83.

Roberts DJ, Jenne CN, Léger C, Kramer AH, Gallagher CN, Todd S, Parney IF, Doig CJ, Yong VW, Kubes P, Zygun DA (2013) A prospective evaluation of the temporal matrix metalloproteinase response after severe traumatic brain injury in humans. J Neurotrauma 30(20):1717–1726PubMed

84.

Shen L-J, Yang S-B, Lv Q-W, Zhang G-H, Zhou J, Guo M et al (2014) High plasma adiponectin levels in patients with severe traumatic brain injury. Clin Chim Acta 427:37–41PubMed

85.

Darwish RS, Amiridze N, Aarabi B (2007) Nitrotyrosine as an oxidative stress marker: evidence for involvement in neurologic outcome in human traumatic brain injury. J Trauma 63(2):439–442PubMed

86.

Clausen F, Marklund N, Lewén A, Enblad P, Basu S, Hillered L (2012) Interstitial F(2)-isoprostane 8-iso-PGF(2α) as a biomarker of oxidative stress after severe human traumatic brain injury. J Neurotrauma 29(5):766–775PubMed

87.

Yu G-F, Jie Y-Q, Wu A, Huang Q, Dai W-M, Fan X-F (2013) Increased plasma 8-iso-prostaglandin F2α concentration in severe human traumatic brain injury. Clin Chim Acta 421:7–11PubMed

88.

Lo T-YM, Jones PA, Minns RA (2010) Combining coma score and serum biomarker levels to predict unfavorable outcome following childhood brain trauma. J Neurotrauma 27(12):2139–2145PubMed

89.

Wolf H, Frantal S, Pajenda GS, Salameh O, Widhalm H, Hajdu S, Sarahrudi K (2013) Predictive value of neuromarkers supported by a set of clinical criteria in patients with mild traumatic brain injury: S100B protein and neuron-specific enolase on trial: clinical article. J Neurosurg 118(6):1298–1303PubMed

90.

Diaz-Arrastia R, Wang KKW, Papa L, Sorani MD, Yue JK, Puccio AM, McMahon P, Inoue T, Yuh EL, Lingsma HF, Maas AI, Valadka AB, Okonkwo DO, Manley GT, TRACK-TBI Investigators (2014) Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma 31(1):19–25PubMedPubMedCentral

91.

Tate CM, Wang KKW, Eonta S, Zhang Y, Carr W, Tortella FC, Hayes RL, Kamimori GH (2013) Serum brain biomarker level, neurocognitive performance, and self-reported symptom changes in soldiers repeatedly exposed to low-level blast: a breacher pilot study. J Neurotrauma 30(19):1620–1630PubMed

92.

Bazarian JJ, Beck C, Blyth B, von Ahsen N, Hasselblatt M (2006) Impact of creatine kinase correction on the predictive value of S-100B after mild traumatic brain injury. Restor Neurol Neurosci 24(3):163–172PubMed

93.

Papa L, Robertson CS, Wang KKW, Brophy GM, Hannay HJ, Heaton S, Schmalfuss I, Gabrielli A, Hayes RL, Robicsek SA (2015) Biomarkers improve clinical outcome predictors of mortality following non-penetrating severe traumatic brain injury. Neurocrit Care 22(1):52–64PubMed

94.

Copin J-C, Rebetez MML, Turck N, Robin X, Sanchez J-C, Schaller K et al (2012) Matrix metalloproteinase 9 and cellular fibronectin plasma concentrations are predictors of the composite endpoint of length of stay and death in the intensive care unit after severe traumatic brain injury. Scand J Trauma Resusc Emerg Med 20:83PubMedPubMedCentral

95.

DeKosky ST, Abrahamson EE, Ciallella JR, Paljug WR, Wisniewski SR, Clark RSB, Ikonomovic MD (2007) Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol 64(4):541–544PubMed

96.

Olivecrona Z, Koskinen L-OD (2012) The release of S-100B and NSE in severe traumatic head injury is associated with APOE ε4. Acta Neurochir 154(4):675–680 discussion 680PubMed

97.

Na Y-J, Kim JH (2013) Understanding cooperativity of microRNAs via microRNA association networks. BMC Genomics 14(Suppl 5):S17PubMedPubMedCentral

98.

Najem D, Rennie K, Ribecco-Lutkiewicz M, Ly D, Haukenfrers J, Liu Q et al (2018) Traumatic brain injury: classification, models and markers. Biochem Cell Biol 96(4):391–406PubMed

99.

Di Pietro V, Ragusa M, Davies D, Su Z, Hazeldine J, Lazzarino G et al (2017) MicroRNAs as novel biomarkers for the diagnosis and prognosis of mild and severe traumatic brain injury. J Neurotrauma 34(11):1948–1956PubMed

100.

Guingab-Cagmat JD, Cagmat EB, Hayes RL, Anagli J (2013) Integration of proteomics, bioinformatics, and systems biology in traumatic brain injury biomarker discovery. Front Neurol 4:61PubMedPubMedCentral

101.

Feala JD, Abdulhameed MDM, Yu C, Dutta B, Yu X, Schmid K et al (2013) Systems biology approaches for discovering biomarkers for traumatic brain injury. J Neurotrauma 30(13):1101–1116PubMedPubMedCentral

102.

Fiandaca MS, Mapstone M, Mahmoodi A, Gross T, Macciardi F, Cheema AK, Merchant-Borna K, Bazarian J, Federoff HJ (2018) Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls. PLoS One 13(4):e0195318PubMedPubMedCentral

103.

Azar S, Hasan A, Younes R, Najdi F, Baki L, Ghazale H et al (2017) Biofluid proteomics and biomarkers in traumatic brain injury. Methods Mol Biol 1598:45–63PubMed

104.

Anada RP, Wong KT, Jayapalan JJ, Hashim OH, Ganesan D (2018) Panel of serum protein biomarkers to grade the severity of traumatic brain injury. Electrophoresis 39(18):2308–2315PubMed

105.

Zou H, Bao WX, Luo BY (2018) Applications of proteomics in traumatic brain injury: current status and potential prospects. Chin Med J 131(18):2143–2145PubMedPubMedCentral

106.

Banoei MM, Casault C, Metwaly SM, Winston BW (2018) Metabolomics and biomarker discovery in traumatic brain injury. J Neurotrauma 35(16):1831–1848PubMed

107.

Hogan SR, Phan JH, Alvarado-Velez M, Wang MD, Bellamkonda RV, Fernández FM, LaPlaca M (2018) Discovery of lipidome alterations following traumatic brain injury via high-resolution metabolomics. J Proteome Res 17(6):2131–2143PubMedPubMedCentral

108.

Orešič M, Posti JP, Kamstrup-Nielsen MH, Takala RSK, Lingsma HF, Mattila I, Jäntti S, Katila AJ, Carpenter KLH, Ala-Seppälä H, Kyllönen A, Maanpää HR, Tallus J, Coles JP, Heino I, Frantzén J, Hutchinson PJ, Menon DK, Tenovuo O, Hyötyläinen T (2016) Human serum metabolites associate with severity and patient outcomes in traumatic brain injury. EBioMedicine. 12:118–126PubMedPubMedCentral

109.

Wolahan SM, Hirt D, Glenn TC (2015) Translational metabolomics of head injury: exploring dysfunctional cerebral metabolism with ex vivo NMR spectroscopy-based metabolite quantification. In: Kobeissy FH (ed) Brain neurotrauma: molecular, neuropsychological, and rehabilitation aspects [Internet]. CRC Press/Taylor & Francis, Boca Raton (FL) [cited 2018 Jul 6]. (Frontiers in Neuroengineering). Available from: http://www.ncbi.nlm.nih.gov/books/NBK299232/

110.

Jayaraman SP, Anand RJ, DeAntonio JH, Mangino M, Aboutanos MB, Kasirajan V et al (2018) Metabolomics and precision medicine in trauma: the state of the field. Shock 50(1):5–13PubMedPubMedCentral

111.

Chitturi J, Li Y, Santhakumar V, Kannurpatti SS (2019) Consolidated biochemical profile of subacute stage traumatic brain injury in early development. Front Neurosci 13:431PubMedPubMedCentral

112.

Servià L, Jové M, Sol J, Pamplona R, Badia M, Montserrat N et al (2019) A prospective pilot study using metabolomics discloses specific fatty acid, catecholamine and tryptophan metabolic pathways as possible predictors for a negative outcome after severe trauma. J Scand J Trauma Resusc Emerg Med 27(1):56

113.

Watt SE, Shores EA, Baguley IJ, Dorsch N, Fearnside MR (2006) Protein S-100 and neuropsychological functioning following severe traumatic brain injury. Brain Inj 20(10):1007–1017PubMed

114.

Marchi N, Bazarian JJ, Puvenna V, Janigro M, Ghosh C, Zhong J, et al. Consequences of repeated blood-brain barrier disruption in football players. PLoS ONE [Internet]. 2013 6 [cited 2018 May 17];8(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590196/

115.

Yi L, Shi S, Wang Y, Huang W, Xia Z, Xing Z et al (2016) Serum metabolic profiling reveals altered metabolic pathways in patients with post-traumatic cognitive impairments. Sci Rep 6:21320PubMedPubMedCentral

116.

Rockswold SB, Rockswold GL, Zaun DA, Zhang X, Cerra CE, Bergman TA, Liu J (2010) A prospective, randomized clinical trial to compare the effect of hyperbaric to normobaric hyperoxia on cerebral metabolism, intracranial pressure, and oxygen toxicity in severe traumatic brain injury. J Neurosurg 112(5):1080–1094PubMed

117.

Carteron L, Bouzat P, Oddo M (2017) Cerebral microdialysis monitoring to improve individualized neurointensive care therapy: an update of recent clinical data. Front Neurol 8:601PubMedPubMedCentral

118.

Puccio AM, Hoffman LA, Bayir H, Zullo TG, Fischer M, Darby J, Alexander S, Dixon CE, Okonkwo DO, Kochanek PM (2009) Effect of short periods of normobaric hyperoxia on local brain tissue oxygenation and cerebrospinal fluid oxidative stress markers in severe traumatic brain injury. J Neurotrauma 26(8):1241–1249PubMedPubMedCentral

119.

Olivecrona M, Rodling-Wahlström M, Naredi S, Koskinen L-OD (2009) S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J Neurol Neurosurg Psychiatry 80(11):1241–1247PubMed

120.

Hendoui N, Beigmohammadi MT, Mahmoodpoor A, Ahmadi A, Abdollahi M, Hasanpour M, Hadi F, Khazaeipour Z, Mousavi S, Mojtahedzadeh M (2013) Reliability of calcium-binding protein S100B measurement toward optimization of hyperosmolal therapy in traumatic brain injury. Eur Rev Med Pharmacol Sci 17(4):477–485PubMed

121.

Shore PM, Thomas NJ, Clark RSB, Adelson PD, Wisniewski SR, Janesko KL, Bayir H, Jackson EK, Kochanek PM (2004) Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markers. J Neurotrauma 21(9):1113–1122PubMed

122.

Tanguy M, Seguin P, Laviolle B, Bleichner J-P, Morandi X, Malledant Y (2012) Cerebral microdialysis effects of propofol versus midazolam in severe traumatic brain injury. J Neurotrauma 29(6):1105–1110PubMed

123.

Mahmoodpoor A, Shokouhi G, Hamishehkar H, Soleimanpour H, Sanaie S, Porhomayon J, Rasouli F, Nader ND (2018) A pilot trial of l-carnitine in patients with traumatic brain injury: effects on biomarkers of injury. J Crit Care 45:128–132PubMed

124.

Hellewell SC, Mondello S, Conquest A, Shaw G, Madorsky I, Deng JV, Little L, Kobeissy F, Bye N, Bellomo R, Cooper DJ, Vallance S, Board J, Morganti-Kossmann MC (2018) Erythropoietin does not alter serum profiles of neuronal and axonal biomarkers after traumatic brain injury: findings from the Australian EPO-TBI clinical trial. Crit Care Med 46(4):554–561PubMed

125.

Poon W, Vos P, Muresanu D, Vester J, von Wild K, Hömberg V, Wang E, Lee TM, Matula C (2015) Cerebrolysin Asian Pacific trial in acute brain injury and neurorecovery: design and methods. J Neurotrauma 32(8):571–580PubMed

126.

Lai X, Wolkenhauer O, Vera J (2016) Understanding microRNA-mediated gene regulatory networks through mathematical modelling. Nucleic Acids Res 44(13):6019–6035PubMedPubMedCentral

127.

Lai X, Bhattacharya A, Schmitz U, Kunz M, Vera J, Wolkenhauer O (2013) A systems’ biology approach to study microRNA-mediated gene regulatory networks. Biomed Res Int 2013:703849PubMedPubMedCentral

128.

Jaber Z, Aouad P, Al Medawar M, Bahmad H, Abou-Abbass H, Kobeissy F (2016) Application of systems biology to neuroproteomics: the path to enhanced theranostics in traumatic brain injury. Methods Mol Biol 1462:139–155PubMed

129.

Rosato A, Tenori L, Cascante M, De Atauri Carulla PR, Martins Dos Santos VAP, Saccenti E (2018) From correlation to causation: analysis of metabolomics data using systems biology approaches. Metabolomics 14(4):37PubMedPubMedCentral

130.

Yu C, Kobeissy F (2015) Systems biology applications to decipher mechanisms and novel biomarkers in CNS trauma. In: Kobeissy FH (ed) Brain neurotrauma: molecular, neuropsychological, and rehabilitation aspects [Internet]. CRC Press/Taylor & Francis, Boca Raton (FL) [cited 2018 Jul 6]. (Frontiers in Neuroengineering). Available from: http://www.ncbi.nlm.nih.gov/books/NBK299223/

Titel: Biomarkers in traumatic brain injury: new concepts
verfasst von: Dana Slavoaca
Dafin Muresanu
Codruta Birle
Olivia Verisezan Rosu
Ioana Chirila
Iulia Dobra
Nicoleta Jemna
Stefan Strilciuc
Pieter Vos
Publikationsdatum: 10.03.2020
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 8/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-019-04238-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Biomarkers in traumatic brain injury: new concepts

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Psychosocial repercussion of migraine: is it a stigmatized disease?

Zerebrovaskuläre Vorerkrankung mit COVID-19-Mortalität assoziiert

Dementia care and COVID-19 pandemic: a necessary digital revolution

Multiple sclerosis: renaming the notorious and historical diagnosis?

Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) in twin sisters with two CD36 frameshift mutations

Comparison of the efficacy of intramuscular botulinum toxin type-A injection into the pectoralis major and the teres major muscles and suprascapular nerve block for hemiplegic shoulder pain: a prospective, double-blind, randomized, controlled trial

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie